13F Pro13F Pro

Velan Capital Investment Management LP

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1848809
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare100.0%$163.2M

AUM History

13fpro.ai/research/fund/velan-capital-investment-management-lp-1848809

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/velan-capital-investment-management-lp-1848809

Velan Capital Investment Management LP 13F holdings — Q2 2026

$164.2M portfolio (+2.9% QoQ) · 51 holdings · Q2 2026 13F · top 10 are 75% of the stock portfolio

Includes $1000K of put/call options ($0 puts, $1000K calls), which 13F rules report at the value of the underlying shares, not the premium at risk. Stocks alone: $163.2M. Weights use the stock portfolio.

All holdings — Velan Capital Investment Management LP (Q2 2026)

51 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
AVTX$AVTXAvalo Therapeutics, Inc.$6.0M+75%
XNCR$XNCRXencor Inc$4.1M+2%
RZLT$RZLTRezolute, Inc.$3.9M—
HRTX$HRTXHERON THERAPEUTICS, INC. /DE/$3.7M—
VRCA$VRCAVerrica Pharmaceuticals Inc.$2.9M—
CCCC$CCCCC4 Therapeutics, Inc.$2.7MNew
EPRX$EPRXEUPRAXIA PHARMACEUTICALS INC.$2.3M—
ADMA$ADMAADMA BIOLOGICS, INC.$2.1MNew
RNTX$RNTXRein Therapeutics, Inc.$1.8MNew
LYEL$LYELLyell Immunopharma, Inc.$1.5M+3%
NSRX$NSRXNasus Pharma Ltd$1.3M—
PROF$PROFProfound Medical Corp.$1.1M-40%
JSPR$JSPRJasper Therapeutics, Inc.$1.1M—
TENX$TENXCALLTENAX THERAPEUTICS, INC.$1000KNew
PTGX$PTGXProtagonist Therapeutics, Inc$454K—

What changed in Q2 2026

Against the previous quarter's 13F: 7 new, 10 added to, 11 trimmed, 5 sold out. Share-count changes; largest moves by dollar size first.

New positions (7)

  • CCCC$CCCCC4 Therapeutics, Inc.$2.7M

    first bought this quarter

  • ADMA$ADMAADMA BIOLOGICS, INC.$2.1M

    first bought this quarter

  • RNTX$RNTXRein Therapeutics, Inc.$1.8M

    first bought this quarter

  • TENX$TENXCALLTENAX THERAPEUTICS, INC.$1000K

    first bought this quarter

  • TECX$TECXTectonic Therapeutic, Inc.$206K

    first bought this quarter

  • ANTX$ANTXAN2 Therapeutics, Inc.$194K

    first bought this quarter

+1 more in the Excel export

Added to (10)

  • IMMX$IMMXImmix Biopharma, Inc.+47%

    now $11.2M · held 5 qtrs, 2 adds in a row

  • AVTX$AVTXAvalo Therapeutics, Inc.+75%

    now $6.0M · held 7 qtrs

  • NMRA$NMRANeumora Therapeutics, Inc.+188%

    now $391K · held 2 qtrs, 2 adds in a row

  • MGNX$MGNXMACROGENICS INC+100%

    now $277K · held 2 qtrs, 2 adds in a row

  • XNCR$XNCRXencor Inc+2%

    now $4.1M · held 2 qtrs, 2 adds in a row

  • EVMN$EVMNEvommune, Inc.+1%

    now $6.0M · held 3 qtrs

+4 more in the Excel export

Trimmed (11)

  • PRAX$PRAXPraxis Precision Medicines, Inc.-12%

    now $29.7M · held 10+ qtrs

  • CTMX$CTMXCytomX Therapeutics, Inc.-78%

    now $450K · held 7 qtrs

  • ABVX$ABVXAbivax S.A.-15%

    now $8.7M · held 4 qtrs

  • VRDN$VRDNViridian Therapeutics, Inc.\DE-89%

    now $184K · held 5 qtrs

  • NSPR$NSPRInspireMD, Inc.-93%

    now $104K · held 10+ qtrs, 2 trims in a row

  • RCKT$RCKTROCKET PHARMACEUTICALS, INC.-80%

    now $205K · held 2 qtrs

+5 more in the Excel export

Sold out (5)

  • ESPR$ESPREsperion Therapeutics, Inc.was $4.7M

    held 2 qtrs

  • KZIA$KZIAKAZIA THERAPEUTICS LTDwas $1.0M

    held 2 qtrs

  • ARWR$ARWRARROWHEAD PHARMACEUTICALS, INC.was $408K

    held 3 qtrs

  • DSGN$DSGNDesign Therapeutics, Inc.was $213K

    held 5 qtrs

  • PMVP$PMVPPMV Pharmaceuticals, Inc.was $91K

    held 6 qtrs

Share

Holdings by quarter

Every 13F Velan Capital Investment Management LP has filed, 18 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Velan Capital Investment Management?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of Velan Capital Investment Management's top 20 holdings: 18/100 (our AI quality score, weighted by position size; 9 of the 20 are scored)

Top 10 since filing

-36.1%

Value-weighted move of the 10 largest stock positions

Turnover

9%

Last quarter; 82% over the last 4

Top 10 weight

75%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

69%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Velan Capital Investment Management LP disclosed 51 positions worth $164.2M in its Form 13F-HR for Q2 2026 — $163.2M in common stock plus $999,585 of put/call option positions (reported at underlying notional value, not premium at risk), led by $PRAX (Praxis Precision Medicines, Inc.) at 18.2% of the equity portfolio, followed by $MPLT and $STRO. During the quarter the fund opened 7 new positions and exited 5 — including a new stake in $CCCC and a full exit from $ESPR. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Velan Capital Investment Management LP’s Form 13F-HR filing with the SEC under CIK 1848809.

Funds like this

managers whose biggest positions overlap Velan Capital Investment Management's
PERCEPTIVE ADVISORS LLC$6.66B 13F book · 6 shared top holdingsPRAXSTROAVRPTGXCormorant Asset Management, LP$1.95B 13F book · 3 shared top holdingsPRAXABVXCRBPVivo Capital, LLC$1.10B 13F book · 6 shared top holdingsPRAXABVXTENXEPRXIkarian Capital, LLC$928.17M 13F book · 6 shared top holdingsABVXPRAXTENXCCCCACUTA CAPITAL PARTNERS, LLC$143.49M 13F book · 4 shared top holdingsPRAXSTROAVTXARTVLogos Global Management LP$2.32B 13F book · 5 shared top holdingsABVXPRAXAVTXMLYS

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Velan Capital Investment Management LP

13F Pro is an AI hedge fund tracker and stock research platform. For Velan Capital Investment Management LP (SEC CIK: 1848809), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Velan Capital Investment Management LP's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.